NDA[removed]S-054 Zoladex (goserelin acetate implant) 3.6 mg

First Page		Document Content
Date: 2011-01-20 14:36:45 Menstrual cycle GnRH agonists Goserelin Peptides Gonadotropin-releasing hormone agonist Prostate cancer Hormone replacement therapy Endometriosis Flutamide Medicine Chemistry AstraZeneca		NDA[removed]S-054 Zoladex (goserelin acetate implant) 3.6 mg Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 433,76 KB Share Document on Facebook

	A biochemical characterization of the major peptides from the Venom of the giant Neotropical hunting ant Dinoponera australis DocID: 1voQS - View Document
	Application Note Quantification of peptides in MS-based proteomics Introduction In this note, we describe how to use the MS peptide quant application on the Lunatic systems. This application is used for quantification o DocID: 1viOs - View Document
	Posters A-Z Achek, Asma Selection of a new TLR4 antagonizing peptides via the phage display technique DocID: 1vbhL - View Document
	Chapter 5 Ribosomal Synthesis of Thioether-Bridged Bicyclic Peptides Nina Bionda and Rudi Fasan Abstract Many biologically active peptides found in nature exhibit a bicyclic structure wherein a head-to-tail cyclic DocID: 1vanS - View Document
	Method Development Strategies Using Polymer-based SPE for the Analysis of Peptides Prior to UPLC-MS/MS Analysis Helen Lodder1, Lee Williams1, Rhys Jones1, Alan Edgington1, Adam Senior1, Geoff Davies1, Steve Jordan1, Clai DocID: 1v36k - View Document